{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"WU-CART-007"},{"type":"CodeName","name":"WU-CART007"},{"type":"CodeName","name":"WU-CART 007"}],"definition":{"html":"A preparation of off-the-shelf (OTS) donor-derived T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the allogeneic anti-CD7 CAR T cells WU-CART-007 specifically recognize and bind to CD7-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD7 is a transmembrane glycoprotein expressed by T cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas.","text":"A preparation of off-the-shelf (OTS) donor-derived T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) directed against the tumor-associated antigen (TAA) CD7, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the allogeneic anti-CD7 CAR T cells WU-CART-007 specifically recognize and bind to CD7-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD7 is a transmembrane glycoprotein expressed by T cells and natural killer (NK) cells and their precursors. It is expressed in the majority of lymphoblastic T-cell leukemias and lymphomas and in a subset of peripheral T-cell lymphomas."},"drugInfoSummaryLink":null,"nciConceptId":"C182072","nciConceptName":"Allogeneic Anti-CD7 CAR-T Cells WU-CART-007","termId":806155,"name":"allogeneic anti-CD7 CAR T cells WU-CART-007","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"allogeneic-anti-cd7-car-t-cells-wu-cart-007"}],"links":null}